JANX Quote, Financials, Valuation and Earnings

Arvinas has a net margin of -6391.57% compared to Janux Therapeutics's net margin of 43.91%. Janux Therapeutics's return on equity of -11.37% beat Arvinas's return on equity of -7.72%.

Janux Therapeutics has a consensus price target of $84.12, signalling upside risk potential of 233.55%. On the other hand Arvinas has an analysts' consensus of $19.42 which suggests that it could grow by 198.26%. Given that Janux Therapeutics has higher upside potential than Arvinas, analysts believe Janux Therapeutics is more attractive than Arvinas.

Janux Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Arvinas has a beta of 2.215, suggesting its more volatile than the S&P 500 by 121.499%.

Janux Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arvinas offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Janux Therapeutics pays -- of its earnings as a dividend. Arvinas pays out -- of its earnings as a dividend.

Janux Therapeutics quarterly revenues are $439K, which are smaller than Arvinas quarterly revenues of $188.8M. Janux Therapeutics's net income of -$23.5M is lower than Arvinas's net income of $82.9M. Notably, Janux Therapeutics's price-to-earnings ratio is -- while Arvinas's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Janux Therapeutics is 110.03x versus 1.10x for Arvinas. Usually stocks with elevated PS ratios are considered overvalued.

Fortress Biotech has a net margin of -6391.57% compared to Janux Therapeutics's net margin of -80.55%. Janux Therapeutics's return on equity of -11.37% beat Fortress Biotech's return on equity of --.

Janux Therapeutics has a consensus price target of $84.12, signalling upside risk potential of 233.55%. On the other hand Fortress Biotech has an analysts' consensus of $10.00 which suggests that it could grow by 461.8%. Given that Fortress Biotech has higher upside potential than Janux Therapeutics, analysts believe Fortress Biotech is more attractive than Janux Therapeutics.

Janux Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Fortress Biotech has a beta of 1.853, suggesting its more volatile than the S&P 500 by 85.291%.

Janux Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fortress Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Janux Therapeutics pays -- of its earnings as a dividend. Fortress Biotech pays out -10.24% of its earnings as a dividend.

Janux Therapeutics quarterly revenues are $439K, which are smaller than Fortress Biotech quarterly revenues of $13.1M. Janux Therapeutics's net income of -$23.5M is lower than Fortress Biotech's net income of -$10.6M. Notably, Janux Therapeutics's price-to-earnings ratio is -- while Fortress Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Janux Therapeutics is 110.03x versus 0.70x for Fortress Biotech. Usually stocks with elevated PS ratios are considered overvalued.

Innoviva has a net margin of -6391.57% compared to Janux Therapeutics's net margin of -52.56%. Janux Therapeutics's return on equity of -11.37% beat Innoviva's return on equity of -8.85%.

Janux Therapeutics has a consensus price target of $84.12, signalling upside risk potential of 233.55%. On the other hand Innoviva has an analysts' consensus of $55.00 which suggests that it could grow by 189.93%. Given that Janux Therapeutics has higher upside potential than Innoviva, analysts believe Janux Therapeutics is more attractive than Innoviva.

Janux Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Innoviva has a beta of 0.353, suggesting its less volatile than the S&P 500 by 64.673%.

Janux Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Innoviva offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Janux Therapeutics pays -- of its earnings as a dividend. Innoviva pays out -- of its earnings as a dividend.

Janux Therapeutics quarterly revenues are $439K, which are smaller than Innoviva quarterly revenues of $88.6M. Janux Therapeutics's net income of -$23.5M is higher than Innoviva's net income of -$46.6M. Notably, Janux Therapeutics's price-to-earnings ratio is -- while Innoviva's PE ratio is 98.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Janux Therapeutics is 110.03x versus 3.79x for Innoviva. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of -6391.57% compared to Janux Therapeutics's net margin of 21.63%. Janux Therapeutics's return on equity of -11.37% beat Pfizer's return on equity of 8.72%.

Janux Therapeutics has a consensus price target of $84.12, signalling upside risk potential of 233.55%. On the other hand Pfizer has an analysts' consensus of $29.50 which suggests that it could grow by 26.5%. Given that Janux Therapeutics has higher upside potential than Pfizer, analysts believe Janux Therapeutics is more attractive than Pfizer.

Janux Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pfizer has a beta of 0.588, suggesting its less volatile than the S&P 500 by 41.208%.

Janux Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 7.29% to investors and pays a quarterly dividend of $0.43 per share. Janux Therapeutics pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

Janux Therapeutics quarterly revenues are $439K, which are smaller than Pfizer quarterly revenues of $13.7B. Janux Therapeutics's net income of -$23.5M is lower than Pfizer's net income of $3B. Notably, Janux Therapeutics's price-to-earnings ratio is -- while Pfizer's PE ratio is 16.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Janux Therapeutics is 110.03x versus 2.13x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.